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new cases of leukemia per 1 million inhabitants ap-
pear in Western countries. ALL is characterized by 
a tremendous clinical variability, prompting a con-
tinuing search for accurate disease outcome pre-
dictors. Thus, the interactions between leukemia 
Acute lymphoblastic leukemia (ALL) is the 
most common type of cancer among children, 
teenagers, and young adults. In 2002 there were 
approximately 1720 children living with acute lym-
phoblastic leukemia in Mexico. every year 60–100 
Cristian Fabian Layton Tovar1, A–D, Hugo Mendieta Zerón2, A, C–F,  
Maria del Socorro Camarillo Romero3, A, E, Yanko V. Fabila Sánchez4, A, C, E,  
Isidoro Tejocote Romero5, B, E
Glycogen Synthase Kinase-3β (GSK-3β)  
and Nuclear Factor Kappa-B (NFKB)  
in Childhood Acute Lymphoblastic Leukemia
1 School of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico 
2 Latin American Scientific Association and Ciprés Medical Group, Toluca, Mexico 
3 Medical Sciences Research Center, Autonomous University of the State of Mexico, Toluca, Mexico 
4 Terranova University, Toluca, México 
5 Hematology and Oncology Service, The Children’s Hospital, Maternal Child of the State of Mexico Institute,  
 Toluca, Mexico
A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; 
D – writing the article; E – critical revision of the article; F – final approval of article
Abstract
Background. Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in early childhood. 
In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3β) has been 
associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the 
mononuclear cells of bone marrow.
Objectives. The aim of the study was to determine the possible role of glycogen synthase kinase 3beta (GSK-3β) 
and nuclear factor kappa beta (NFKB) as prognostic variables in pediatric patients with ALL.
Material and Methods. This was a  descriptive, transversal, and observational study. Bone marrow and blood 
samples were obtained from 30 children with newly-diagnosed ALL, who were seen at the Hematology-Oncology 
Service, Hospital para el Niño (HPN), Toluca, Mexico, from 2014‒2015. Anthropometric variables, clinical lab 
results, immunophenotype and cytogenetic abnormalities were registered. GSK-3β was evaluated through immu-
nohistochemistry, and NFKB messenger RNA (mRNA) with real-time polymerase chain reaction (qPCR). The cases 
of ALL were classified into two groups of risk: high and habitual.
Results. Thirty patients were included in this study, with a mean age of 7.1 years (range 2‒13 years). Twenty-one 
were male and 9 female. Employing the morphological classification, 26 patients had type L1 ALL and the remain-
ing 4 patients had type L2 ALL. Abnormal genes were found in 7 (23.33%) patients, ETV-RUNX1 in 3, followed 
by TCF3-PBX1 (two), STL1-TAL1 (one), and BCR-ABL1 (one). NFKB relative expression levels, in comparison to 
the GSK-3β immunohistochemistry results of the bone marrow samples, showed significant differences between 
positive and negative cases (p = 0.001) and between weak-positive and negative cases (p = 0.002).
Conclusions. These results suggest that GSK-3β may be a prognostic biomarker in childhood ALL (Adv Clin Exp 
Med 2016, 25, 6, 1139–1147).
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cells and the microenvironment of the bone mar-
row are determinant to generate changes in the 
cell signaling pathways associated with cell sur-
vival. The molecular signaling pathways associated 
with the hematopoiesis process are varied but de-
regulation in one or more points should be deci-
sive in ALL development. Moreover, the cytoge-
netic pattern is an important determinant of ALL 
development; for example, t(1,19), t(4,11), t(12,21) 
and t(9,22) affect the expression of the enzymes 
that regulate the intracellular signaling process [1]. 
As we know, immunophenotype, age, race, white 
blood cell (WBC) count, and gender are important 
prognostic factors.
Glycogen synthase kinase 3 (GSK-3) is a  ser-
ine/tyrosine kinase identified in skeletal muscle. 
To date, two isoforms of GSK-3 have been reported: 
the first, 51 kDa (GSK-3α), and the second, 47 kDa 
(GSK-3β). The activity of GSK-3 can be inhibited by 
Akt-mediated phosphorylation at Ser21 in GSK-3α 
and at Ser9 in GSK-3β. The aberrant expression of 
GSK-3β has been demonstrated in metabolic dis-
orders and in hematopoietic stem cell differenti-
ation and proliferation  [2]. Several studies have 
been performed by means of cell culture and im-
munohistochemistry and have shown that GSK-3β 
is found significantly accumulated in the nuclei of 
cells in patients with ALL. Furthermore, selective 
inhibition of GSK-3β induces cell death mediated 
by downregulation of the transcriptional activity of 
hematopoietic nuclear factor kappa-light-chain-en-
hancer of activated B cells (NFKB). Thus, GSK-3β 
inhibitors significantly decreased NFKB expression, 
generating gene suppression and stimulating apop-
tosis in vitro, which suggested its being a novel, in-
teresting target in ALL treatment  [3]. Even more 
so, the activation process of NFKB in leukemic cells 
is associated with different micro-environmental 
stimuli. However, determination of the biomarkers 
associated with the prognosis and treatment of ALL 
in the last decade has been insufficient.
The  NFKB signaling pathway has exhibited 
constitutive aberrant activation in various hema-
tologic malignancies. In fact, NFKB plays an im-
portant role as the mediator of different processes, 
including immunity, inflammation, cancer pro-
motion, and tissue regeneration  [4]. Moreover, 
NFKB regulates multiple cell processes including 
survival, proliferation, and migration. Alterations 
of the NFKB signaling pathway have been asso-
ciated with the survival of leukemic cells. In ad-
dition, selective inhibition of NFKB in in vitro 
studies has demonstrated the elimination of these 
with minimal effects on normal stem cells [5].
The principal aim of this study was to determine 
whether NFKB and GSK-3β expression in child-
hood ALL could be useful as prognostic variables.
Material and Methods
Patients
All children diagnosed with ALL from Febru-
ary 2014 to March 2015 at the Hospital para el Ni-
ño (HPN), Instituto Materno Infantil del Estado de 
México (IMIEM), Toluca, Mexico, were invited to 
participate in the study. The  patients were classi-
fied into two groups by risk: a) habitual risk, and b) 
high risk. Patients were not included in this study if 
they suffered from another chronic disease. The es-
tablished treatment was that recommended by the 
St. Jude Children’s Research Hospital [6].
General Information
The  clinical data was obtained from the pa-
tient’s clinical database file (Histoclin v. 2.0, 
Palmera Sistemas, Mexico City, Mexico). All chil-
dren were measured for height (m) and weight 
(kg). Body mass index (BMI) was calculated as 
weight (kg) divided by height squared (m2).
Laboratory Analysis
Biochemical and immunophenotype studies 
were performed at the Clinical Laboratory, HPN, 
IMIEM. Immunohistochemical and molecular 
analyses were conducted at the Molecular Biolo-
gy Laboratory, Medical Sciences Research Center 
(CICMED), Autonomous University of the State 
of Mexico (UAEMex).
Biochemical Studies
Blood samples were collected into Vacutainer™ 
tubes and centrifuged to separate serum from 
plasma to measure fasting venous serum glucose 
(mg/dL), uric acid (mg/dL), albumin (mg/dL), 
cholesterol (mg/dL) and triacylglycerols (mg/dL) 
(Hitachi 911, Roche Diagnostics, San Francisco, 
USA) and hematic biometry (KX-21N™, Sysmex, 
Mundelein, USA). All measurements followed 
standardized procedures according to the Interna-
tional Federation of Clinical Chemistry and Labo-
ratory Medicine (IFCC).
Immunophenotype
Peripheral blood and bone marrow samples 
were processed in all cases. Bone marrow sam-
ples were collected and stored under deep-freez-
ing conditions (‒80°C) (Revco Value® Thermo 
Scientific, Waltham, USA) until their use. Immu-
nophenotype was determined by flow cytometry 
(Gallius, Beckman-Coulter, Indianapolis, USA). 
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The  markers used were as follows: CD34; CD45; 
CD117, HLA-DR and TdT (immature cells); B-
lymphoid lineage (CD10, CD19, CD20, CD22, and 
CD79a); T-lymphoid lineage (CD3 and CD7), my-
eloid lineage marker CD13, and the myeloperoxi-
dase (MPO) marker. The chromosomal rearrange-
ments analyzed are shown in Table 1.
Gene Expression
mRNA Extraction
Approximately 200  μL of each sample was 
suspended in 300  μL of ACK buffer (Lonza, San 
Francisco, USA) to isolate the mononuclear cells 
of bone marrow (MCBM). RNA  was extract-
ed from MCBM using Magna Pure LC RNA Iso-
lation Kit III-Tissue (Roche) in the Magna Pure 
LC 2.0 Instrument (Roche, Penzberg, Germa-
ny). The A260/280 nm absorbance ratio was > 1.8 
(quality) and total RNA concentration was calcu-
lated by determining absorbance at 260  nm with 
the NanoPhotometer (Implen GmbH, München, 
Germany).
Real-time PCR
Reverse transcription and quantitative real-
time PCR (qPCR) were performed with the 7500 
Fast Real Time PCR System (Applied Biosystems, 
Cheshire, UK), employing the Sybr Green one-step 
RT-PCR kit (Sigma-Aldrich, Foster City, USA), 
mixing 0.4 mM of each primer in a  final volume 
of 25 μL, the final concentration of each gene was 
optimized with the Taguchi method. The  qPCR 
program included 30  min at 43°C, 2  min at 
95°C; 40 cycles of 15 s at 95°C, 1 min at 60°C fol-
lowed by a melting curve. The annealing temper-
ature for all primers was 60°C. The  comparative 
threshold cycle (CT) method was utilized to cal-
culate fold amplification as follows: 2–ΔΔCT, where 
ΔΔCT = (CT-target − CT-reference) treated-sam-
ple − (CT-target − CT-reference) calibrator-sam-
ple. Calibrator-sample refers to the expression 
level (×1) of the target gene normalized to the con-
stitutive gene [7].
The primers used in the experiments were de-
signed using the Primer Quest web tool (Integrat-
ed DNA Technologies, Inc., Los Angeles, USA) and 
synthesized in the Unit of Synthesis and DNA Se-
quencing, Institute of Biotechnology, Autonomous 
University of Mexico (UNAM) (Cuernavaca, More-
los, Mexico). A Basic Local Alignment Search Tool 
(BLAST) search was performed on primer sequenc-
es to ensure that oligos hybridized only to specific 
products. Sequences of the primers utilized in the 
analysis were as follows: glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), (NCBI: NM_002046.5), 
forward: 5-CTTTGGTATCGTGGAAGGACTC-3, 
reverse: 5-GTAGAGGCAGGGATGATGTTCT-3, 
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step, the slices were dewaxed with phosphate-buff-
ered saline (PBS), baked, and preserved under 4°C 
refrigeration until reading of the GSK-3β immuno-
histochemical staining. GSK-3β immunohistochem-
ical staining was performed in accordance with the 
instructions of the manufacturer provided by Cal-
biochem, using biotin-streptavidin and peroxidase 
for the immunohistochemical technique. PBS was 
employed to replace the antibody and as a negative 
control. Images were captured using a digital cam-
era (LABOMED Microscope with an iVU 3100 cam-
era). We used the PIXEL PRO 2.8 color image analy-
sis system to calculate mean optical density (MOD).
Statistical Analysis
For normally distributed variables, we used 
the Student t-test, and for non-normally distrib-
uted variables, we utilized the Mann-Whitney 
U test. Linear regression analysis, with the predic-
tive variables “deceased” or “alive” and receiver 
operating characteristics (ROC) curves reporting 
area under the curve (AUC) and confidence inter-
val (CI) were also employed. Multivariate analysis 
was performed in order to isolate the GSK-3β and 
NFKB effect on clinical outcomes. Event free sur-
vival (EFS), leukemia-free survival (LFS) and over-
all survival (OS) were calculated for the examined 
patients. Any p-value  ≤  0.05 was considered sig-
nificant. All analyses were performed using SPSS v. 
20 statistical software (IBM, Armonk, North Cas-
tle, USA).
Ethics
The present study was approved by the HPN 
Ethics Committee (Code: EI/136/2014) and was 
conducted in accordance with the Helsinki Dec-
laration (Fortaleza, Brazil). Written informed con-
sent was obtained from parents or patients, and in-
formed consent was obtained from the children.
Results
General Characteristics
Thirty patients were included in this study, 
with a mean age of 7.1 years (range, 2–13 years), 
13 with habitual risk and 17 with high risk. Three 
patients (one of habitual risk and two of high risk) 
were referred to another medical hospital. Dur-
ing the first 30 days after treatment with chemo-
therapy, the EFS for treatment failure (death or re-
lapse) was 86.66%, LFS was 76.66% and OS was 
90%. The single relapse case was still alive after the 
follow-up period of the study. Three deaths were 
recorded within the first week after treatment. 
Table 2 shows the general data of the groups and in 
Table 3 the same information is disaggregated by 
the type of leukemia. The majority of patients were 
male (21), with a  female-to-male ratio of 0.3  :  1. 
Fever, pallor, manifestations of bleeding, hepato-
splenomegaly, and lymphadenopathy were com-
mon clinical manifestations. No patient had a cen-
tral nervous system (CNS) disease.
Immunophenotype
Using the morphological classification, 26 pa-
tients had L1 and the remaining 4 had L2 ALL type. 
In  23  patients (76.6%), chromosomal rearrange-
ment analysis revealed the absence of the fusion 
gene. ETV-RUNX1 was the most common fusion 
gene abnormality (3 patients), followed by TCF3-
PBX1 (2  patients), STL1-TAL1 (1 patient), and 
BCR-ABL1 (1 patient).
We obtained the results of 28 different chromo-
somal rearrangements that were related with the de-
velopment of ALL, without finding significant dif-
ferences in NFKB expression levels. When analyzing 
a correlation between clinical features and molecu-
lar cytogenetics, it was found that the STL1-TAL1 
fusion gene exhibited the lowest hemoglobin level, 
with a base value of 11.3 g/dL, while the highest lev-
el was observed in ALL with the BCR-ABL1 fusion 
gene, with a  mean value of 12.7  g/dL. The  TCF3-
PBX1 fusion gene demonstrated the lowest white 
blood cell count, with a base value of 6.55/mm3, and 
the highest count was found in ALL with the STL1-
TAL1 fusion gene, with a mean value of 455/mm3. 
The  STL1-TAL1 fusion gene showed the lowest 
platelet count, with a base value of 29/mm3, while 
the highest count was found in ALL with the BCR-
ABL1 fusion gene, with a mean value of 370/mm3.
Gene Expression
On analyzing the CT values of NFKB expres-
sion, the differences between the two groups of 
risk were not statistically significant. Nonetheless, 
the mean NFKB expression level showed a trend to 
be higher in the high-risk than in the habitual-risk 
group (Table 2).
To analyze whether NFKB demonstrated a re-
lationship with the ALL type, we performed addi-
tional analyses according to the immunophenotype 
pattern, finding statistically significant differences 
between Pre B-ALL and other ALL types. Interest-
ingly, there were no significant differences either 
in anthropometric measurements or in hemato-
logic parameters (Table 3).
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Immunohistochemistry
The  immunohistochemistry of GSK-3β re-
vealed 8 patients who were positive, 8 patients who 
were weak-positive, and 15 patients who were neg-
ative. Table 4 illustrates the distribution of immu-
nohistochemistry results of the bone marrow sam-
ples by risk classification.
Through the Pearson test, there was a  posi-
tive correlation between high-risk patients and the 
GSK-3β expression (R = 0.741; p = 0.010). Inter-
estingly, by doing an intragroup correlation with 
NFKB expression, those patients with a  positive 
or weak-positive result in GSK-3β showed a posi-
tive correlation with NFKB expression (R = 0.910; 
p ≤ 0.001).
When grouping patients under two conditions, 
that is, a) failure (deceased or relapsed) and b) alive 
with typical treatment, there were 5 variables with 
a  statistically significant difference: body surface 
(p = 0.034); urea (p = 0.036); blood urea nitrogen 
(BUN) (p  =  0.044); lactate dehydrogenase (LDH) 
(p = 0.027), and total bilirubin (TB) (p = 0.006).
By means of the linear regression analysis, pre-
dictive variables for “deceased” or “alive” comprised 
uric acid (mg/dL), hemoglobin (g/dL), and GSK-3β 




























Age (years) 9 (2–13) 6 (3–13)
Weight (kg) 22.5 (12.30–71.20) 20.00 (13.28–77.00)
Height (cm) 125.00 (80.00–164.00) 126.5 (98.00–176.00)
BMI (kg/m2) 17.11 (14.10–26.47) 15.61 (13.28–26.22)
Body surface (m2) 0.90 (0.55–1.81) 0.77 (0.48–1.89)
Waist circumference (cm) 55 (47–63) 57.00 (50.00–104.00)
WBC (c/mm3) 5.10 (1.70–44.0) 2.70 (1.30–455.00)
Hemoglobin (g/dL) 11.90 (6.20–15.80) 10.90 (5.60–17.60)
Hematocrit (%) 30.15 (26.70–43.70) 31.80 (15.20–53.40)
RBC (c/mm3) 3.76 (1.88–5.12) 3.73 (1.85–5.78)
Lymphocytes (c/mm3) 2.88 (0.88–8.20) 1.78 (0.00–6.61)
Monocytes (c/mm3) 0.15 (0.00–0.70) 0.10 (0.00–161.00)
Eosinophils (c/mm3) 0.00 (0.00–0.14) 0.00 (0.00–0.06)
Granulocytes (c/mm3) 0.90 (0.00–7.00) 0.22 (0.00–6.80)
Blasts (%) 0.00 (0.00–97.00) 0.00 (0.00–100.00)
Platelets (c/mm3) 180 (4–373) 29 (2–407)
* – results expressed in mean and range, except “sex”, “cytogenetic risk” and “clinical outcome” which are expressed 
in frequency and percentage; BMI – body mass index; c – cells; CR – clinical remission; NCR – non-clinical remission; 
NFKB – nuclear factor kappa B; RBC – red blood cells; RU – relative units; WBC – white blood cells.
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(OD relative units). These results were constant on 
analyzing only males and when the groups were 
“failure” and “alive with typical treatment”.
In  the ROC analysis, when the options were 
“deceased” vs. “alive”, showed TB (AUC: 932, CI: 
0.794–1.070) to be the only significant progno-
sis variable (p = 0.013); while using the same ap-
proach with the options “failure” vs. “alive with 
typical treatment”, yielded GSK-3β (AUC: 962, CI: 
0.858–1.065) as the only significant prognosis vari-
able (p = 0.042).
Finally, GSK-3β (OD relative units) had 
a significant value (p = 0.037) as a survival prog-
nosis factor when introducing the “risk classi-
fication” and the presence of “cytogenetic al-
terations” as factors in the multivariate lineal 
regression model.
Discussion
ALL is a disease in which micro-environmen-
tal interactions and abnormalities in the genome 
and the epigenome accumulate, enabling cells to 
avoid the control mechanisms of the cell cycle. 
This affects the effectiveness of the repair systems 
as a result of exposure to harmful endo- and exog-
enous damaging agents [8, 9].
We did not find statistically significant differ-
ences in hematic biometry by risk stage, outcome 
or ALL type, this suggesting that implementation 
of molecular biomarkers is one of several require-
ments for the prognosis of childhood ALL. ETV-
RUNX1 and TCF3-PBX1 fusion genes were found 
in a higher proportion of cases compared to that 
reported in literature [10].









































































































































































BMI – body mass index; c – cells; NFKB – nuclear factor kappa B; RBC – red blood cells; RU – relative units; WBC – white 
blood cells; * significance ≤ 0.05.
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Immunophenotype and chromosomal altera-
tions comprise some of the several outcome tools 
in patients with ALL. However, we did not find 
significant differences between the two clinical-
risk groups (high and habitual) related to the ex-
pression of cell surface markers.
In human tumorigenesis, NFKB is an important 
factor in cancer cell survival [11]. In fact, alterations 
to the NFKB pathway are particularly recognized in 
ALL and other leukemias, for example, its regulation 
should facilitate the apoptosis of leukemic cells [12].
Recently, GSK-3β has been associated with 
the regulation of NFKB activity. For first instance, 
GSK-3β inactivation decreases the activation path-
way of NFKB, generates gene suppression, and stimu-
lates apoptosis in vitro [13]. According to Hu in 2011, 
GSK-3β inhibitors significantly decreased NFKB ex-
pression, suggesting that it is a new, interesting target 
in ALL treatment, these results supporting the NFKB/
GSK-3β relationship [14, 15]. In our analysis, immu-
nohistochemistry to GSK-3β demonstrated 8 patients 
who were positive, 8 patients who were weak-positive, 
and 15 patients who were negative, these results show-
ing a positive correlation with NFKB expression lev-
els. However, NFKB expression and its role in the de-
velopment of ALL may be a result of interactions with 
GSK-3β, a perspective to analyze.
To  date, there has been scarce information ex-
plaining the role of GSK-3β in relation to surviv-
al and proliferation pathways [16, 17]. In this line of 
research, our previously mentioned results indicate 
that increased expression of GSK-3β may be direct-
ly associated with regulation of the NFKB pathway. 
In  addition, the function of NFKB and GSK-3β in 
leukemic cells indicates that this molecular pathway 
might be a potent therapeutic target [18, 19], and that 
prognoses should obtain better results utilizing them.
In pediatric ALL cells, the GSK-3β/NFKB rela-
tionship has already been studied [20–23]; howev-
er, while the results suggest an influence of GSK-3β 
on the transcriptional activity of NFKB p65, there 
were no changes in its expression in this initial ap-
proach. On the other hand, the use of selective 
GSK-3β inhibitors is a  target in the treatment of 
pediatric ALL. Furthermore, NFKB expression lev-
els and GSK-3β should be associated with the clini-
cal risk of the pediatric patients.
A  limitation of our study is the lack of com-
parison among different chemotherapy schemes, 
but the number of patients needed to do so, implies 
a time beyond the perspective of our main objective, 
which is to evaluate new options of prognosis mark-
ers in the pediatric population attended in Mexico.
In  conclusion, the current study revealed an 
interaction between the NFKB expression levels 
and GSK-3β signaling pathways in patients with 
ALL. Thus, the GSK-3β expression pattern needs 
to be studied as a prognosis factor, without ruling 
out other signaling pathways such as PI3K/PTEN/
Akt/mTOR and Ras/Raf/MEK/ERK and the mam-
malian target of rapamycin (mTOR).






GSK-3β positive  0 (0.00%)  8 (47.06%)
weak positive  5 (38.47%)  3 (17.64%)
negative  9 (69.23%)  6 (35.30%)
CD3 positive  0 (0.00%)  2 (11.76%)
negative 13 (100.00%) 15 (88.24%)
CD5 positive  0 (0.00%)  1 (5.88%)
negative 13 (100.00%) 16 (94.12%)
CD10 positive 11 (84.62%) 12 (70.59%)
negative  2 (15.38%)  5 (29.41%)
CD13 positive  1 (7.69%)  0 (0.00%)
negative 12 (92.31%) 13 (100.00%)
CD19 positive 12 (92.31%) 13 (100.00%)
negative  1 (7.69%)  4 (23.53%)
CD20 positive  2 (15.38%)  3 (17.65%)
negative 11 (84.62%) 14 (82.35%)
CD22 positive  8 (61.54%) 10 (58.82%)
negative  5 (38.46%)  7 (41.18%)
CD34 positive  7 (53.85%)  6 (35.29%)
negative  6 (46.15%) 11 (64.71%)
CD45 positive 12 (92.31%) 15 (88.24%)
negative  1 (7.69%)  2 (11.76%)
CD79a positive 12 (92.31%) 13 (76.47%)
negative  1 (7.69%)  4 (23.53%)
CD117 positive  2 (15.38%)  4 (23.53%)
negative 11 (84.62%) 13 (76.47%)
HLADR positive 12 (92.31%) 13 (76.47%)
negative  1 (7.69%)  4 (23.53%)
MPO positive  0 (0.00%)  1 (5.88%)
negative 13 (100.00%) 16 (94.12%)
TdT positive  7 (53.85%)  7 (41.18%)
negative  5 (38.46%) 10 (58.82%)
* – results expressed in frequency and percentage.
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